B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silexion Therapeutics Corp - Ordinary Shares (NQ: SLXN )

2.220 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,721
Open 2.220
Bid (Size) 2.250 (1)
Ask (Size) 2.290 (2)
Prev. Close 2.220
Today's Range 2.220 - 2.220
52wk Range 0.2070 - 4.650
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises
From PESG Research
Via Business Wire

Performance

YTD
+13.85%
+13.85%
1 Month
+593.75%
+593.75%
3 Month
+261.98%
+261.98%
6 Month
+13.85%
+13.85%
1 Year
+13.85%
+13.85%

More News

Read More
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Agilent, Bath & Body Works And 3 Stocks To Watch Heading Into Monday
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
What's Going On With Silexion Therapeutics Shares Wednesday?
Via Benzinga
US Stocks Mostly Lower; Target Posts Downbeat Earnings
Via Benzinga
Ilan Hadar, CEO of Silexion Therapeutics Corp. (NASDAQ: SLXN), to Present at NobleCon20
Via Investor Brand Network
Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Via News Direct
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit
Via News Direct
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Silexion Investigational Pancreatic Cancer Treatment Shows Promise In Animal Studies
Via Benzinga
Market Alert: Silexion Therapeutics (NASDAQ: SLXN) Sees Record Volumes Following Breakthrough Preclinical Data for SIL-204
Via News Direct
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Silexion Therapeutics Unveils Promising Preclinical Data for SIL-204 Just Days After New LODER Data: Advancing the Fight Against Pancreatic Cancer
Via AB Newswire
Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies
From Silexion Therapeutics Corp.
Via Business Wire
Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise
Via Benzinga
Silexion Therapeutics Reports Promising Phase 2 Data for Non-Resectable Pancreatic Cancer Treatment
Via AB Newswire
Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer
From Silexion Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.